Health Care · Pharmaceutical Preparations

ACRS Aclaris Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1557746130 filings
Russell 2000

ACRS at a glance

Aclaris Therapeutics, Inc. (ACRS, SEC CIK 1557746) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Aclaris Therapeutics, Inc. (ACRS) shares worth $154.5 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$7.8M
−58.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$154.5M · −1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $1.481M, down $1.818M YoY from $3.299M, primarily lower licensing revenue
  • Q3 net loss $18.510M vs $14.614M YoY, operating loss $21.344M vs $17.149M
  • Strongest R&D growth: ATI-052 expense $5.906M, up $4.069M YoY; ATI-9494 $4.676M, up $3.272M
  • Cash and securities $204.6M, including $20.4M cash and $184.2M marketable securities
  • Nine-month operating cash use $62.076M vs $33.982M; management expects losses and additional capital needs near term

Risk Factors

  • Liquidity risk: $204.6 million cash, cash equivalents and marketable securities against $59.8 million nine-month net loss
  • Financing risk: October offering added $46.7 million net proceeds through 7,785,714 shares and 6,500,000 pre-funded warrants
  • Marketable-securities concentration: $184.2 million fair value, including $70.5 million corporate debt securities maturing within one to three years
  • Regulatory milestone exposure: $10.7 million contingent consideration tied to Confluence regulatory and commercial milestones

AI summary of the ACRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis
  • Results could determine bosakitug’s development path and competitive positioning in atopic dermatitis

Item 8.01: Other Events

  • Bosakitug Phase 2 missed its Week 24 primary endpoint and secondary endpoints, materially weakening its eczema development outlook
  • Robust TSLP target engagement and immune biomarker downregulation did not translate into clinical efficacy

Item EX-99.1: Item EX-99.1

  • Phase 2 ADMIRATION trial failed primary and secondary endpoints in moderate-to-severe atopic dermatitis
  • Bosakitug showed robust TSLP target engagement but no demonstrated clinical efficacy, weakening its standalone AD opportunity

Item EX-99.2: Item EX-99.2

  • Phase 2b A LP HA trial initiated for modzatinib in moderate-to-severe lichen planus, expanding the lead asset into a disease with no FDA-approved targeted therapies
  • Approximately 100 participants across oral erosive, cutaneous and lichen planopilaris cohorts, with two dose levels versus placebo
Filed Nov 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.5M versus $3.3M, while net loss widened to $18.5M from $14.6M
  • Cash, equivalents and marketable securities $204.6M, with October financing adding $50.0M gross proceeds

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Aclaris financial results for the quarter ended September 30, 2026
  • Nine-month results through September 30, 2026 also announced
Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 1b proof-of-concept success for ATI-052 in AD and asthma, materially validating dual TSLP/IL-4Rα targeting
  • AD trial: 14 patients, 45% placebo-adjusted EASI improvement and 43% placebo-adjusted itch improvement at day 57

Item 8.01: Other Events

  • Preliminary cash, equivalents and marketable securities of $204.6M at September 30, 2026, supporting continued development but subject to material adjustment
  • ATI-052 showed 45% placebo-adjusted EASI improvement at day 57 in 14-patient atopic dermatitis trial

Item EX-99.2: Item EX-99.2

  • Phase 1b proof-of-concept achieved in atopic dermatitis and asthma, supporting ATI-052 advancement to Phase 2
  • Atopic dermatitis: 58% EASI reduction and 78% EASI-50 response versus 13% and 0% placebo at Day 57

Item 2.02: Results of Operations and Financial Condition

  • Item 2.02 points investors to Item 8.01 for Aclaris’ cash, cash equivalents and marketable securities as of September 30, 2026
  • Liquidity disclosure is the filing’s only financial update, relevant to funding capacity and near-term operations

Item 7.01: Regulation FD Disclosure

  • ATI-052 Phase 1b proof-of-concept primary analysis results announced in atopic dermatitis and asthma
  • Anti-TSLP/IL-4Rα bispecific antibody data marks an early clinical validation milestone for Aclaris’ pipeline

AI summaries of ACRS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ACRS

Don't miss the next ACRS filing

  • Alerts as it files. A push when ACRS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ACRS, by share count.
  • Ask anything. An AI agent that reads every ACRS filing and answers with sources.

ACRS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kolbeck Roland WilhelmMAug 1, 2026-
Kolbeck Roland WilhelmFAug 1, 2026$5.20
Kolbeck Roland WilhelmMAug 1, 2026-
GOWEN MAXINEMJun 5, 2026-
SCHIFF ANDREW NMJun 5, 2026-
Mehra AnandMJun 5, 2026-
Humphries William D.MJun 5, 2026-
MILANO VINCENTMJun 5, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$18.7M$7.8M
Operating Income--$141.9M-$76.4M
Net Income-$88.5M-$132.1M-$64.9M
Op. Margin--758.2%-975.9%
Net Margin--705.5%-829.6%
Balance Sheet
Total Assets$197.4M$220.3M$160.5M
Equity-$155.6M$103.1M
ROE--84.9%-63.0%
Per Share
EPS$-1.27$-1.71$-0.53
Cash Flow
Operating CF--$20.1M-$47.1M
CapEx$1.3M$121K$111K

Source: XBRL data in Aclaris Therapeutics, Inc. (ACRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ACRS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ACRS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$154.5M
Q2 202627$152.1M
Q1 202626$102.4M
Q4 202524$87.6M
Q3 202524$57.7M
Q2 202522$42.4M
Q1 202519$31.3M
Q4 202414$31.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 182 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ACRS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KOct 27, 2026Analysis-
8-KOct 27, 2026Analysis-
SC 13GSep 21, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Aug 4, 2026--
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 4, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
4May 5, 2026--
8-KApr 28, 2026Analysis-
4Apr 27, 2026--
SC 13GApr 7, 2026-
SC 13GMar 17, 2026-
8-KMar 11, 2026Analysis-

Related Health Care companies

All Health Care →

ACRS SEC filings: frequently asked questions

Which institutions hold ACRS stock?

As of September 30, 2026, the largest Aclaris Therapeutics, Inc. (ACRS) holders among the 13F filers tracked by SignalX were BlackRock ($54.6 million), Vanguard Capital Management LLC ($30.8 million), State Street Corp ($19.4 million), Citadel Advisors LLC ($9.3 million), Vanguard Portfolio Management LLC ($7.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ACRS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53. The figures come from the XBRL data in the 10-K.

What did ACRS report in its latest 8-K?

Aclaris Therapeutics, Inc. (ACRS) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Phase 2 ADMIRATION top-line results announced for bosakitug in moderate-to-severe atopic dermatitis.

What are the latest ACRS SEC filings?

Aclaris Therapeutics, Inc. (ACRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 4, 2026.

What is ACRS's SEC CIK number?

Aclaris Therapeutics, Inc. (ACRS)'s SEC Central Index Key (CIK) is 1557746. EDGAR lists every ACRS filing under that number.

Ask anything about ACRS

The research agent reads ACRS's filings, financials, insider trades and 13F holders, then answers with sources.